The BLA is supported by the primary analysis data of the IGNYTE trial, evaluating RP1 combined with nivolumab in patients with anti-PD-1 failed melanoma. A confirmatory Phase 3 trial, IGNYTE-3 ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback